Harder to attach positive impact - but if CYP ever turns into a profitable business IF - the single standout positive would be from a guy that isn't there anymore and who pretty much stuffed up on behalf of a lot of platform buyers at Exopharm. Ian Dixon.
As a shareholder or potential shareholder you and I can contribute with ideas and criticisms - in the sense that if they are valid they will be recognized as valid potentially even if the ideas aren't ticked. What rings true etc. Power of an idea whose time has come and all that.
But "I'd take the cash and sing from the same hymn book" means you aren't offering anything different AND in doing that as pledge you'd have the negative associations of being pledge (so they probably wouldn't vote for you over a stranger - my opinion of the MSB forum of you only) - as I would have the negative associations of being JB1975.
I can and have identified specific things that could be done at both companies. I can't recall you doing that - you've suggested that CYP needs an office in the US - but that's an additional spend. More spending without clear benefit isn't going to be a winner with self interested shareholders.
At MSB I've specifically identified a potency assay with INF gamma included in the matrix approach AND doing another (adult) trial - I think that would get MSB going forward - whereas current trajectory won't - it needs the FDA to fail logically or ethically or both.
At CYP I'd change the KPIs and make them explicit and public. Has to start with Kilian (being accountable against objective metrics with real money and real consequences) because if the CEO isn't objectively accountable - no one is. The CEO judges and assesses the performance of the other roles.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)